Roche limits biosim damage to cancer blockbusters, but it's still early, execs warn

16th October 2019 Uncategorised 0

The past quarter was the first one Roche faced off biosimilars to Herceptin and Avastin in the U.S. Though the copycats’ pullback on the two originators’ sales was weaker than what industry watchers had expected, execs still warn of “a significant impact” for the coming year.

More: Roche limits biosim damage to cancer blockbusters, but it's still early, execs warn
Source: fierce